Consolidation continues in the CRO space, with the acquisition of Chiltern by LabCorp being just the latest example of top CROs expanding and increasing their breadth of offerings. As large CROs continue to acquire smaller competitors, can sponsor companies expect to benefit from this development? I recently spoke to Andrew Schafer, president of research firm Industry Standard Research (ISR), about the consolidation and what he thinks it will mean for the industry. Continue reading at clinicalleader.com

ISR CUSTOMERS